Shamburek R D, Pentchev P G, Zech L A, Blanchette-Mackie J, Carstea E D, VandenBroek J M, Cooper P S, Neufeld E B, Phair R D, Brewer H B, Brady R O, Schwartz C C
Molecular Disease Branch, National Institutes of Health, Bethesda, MD 20892, USA.
J Lipid Res. 1997 Dec;38(12):2422-35.
Niemann-Pick C disease (NP-C) is a rare inborn error of metabolism with hepatic involvement and neurological sequelae that usually manifest in childhood. Although in vitro studies have shown that the lysosomal distribution of LDL-derived cholesterol is defective in cultured cells of NP-C subjects, no unusual characteristics mark the plasma lipoprotein profiles. We set out to determine whether anomalies exist in vivo in the cellular distribution of newly synthesized, HDL-derived or LDL-derived cholesterol under physiologic conditions in NP-C subjects. Three affected and three normal male subjects were administered [14C]mevalonate as a tracer of newly synthesized cholesterol and [3H]cholesteryl linoleate in either HDL or LDL to trace the distribution of lipoprotein-derived free cholesterol. The rate of appearance of free [14C]- and free [3H]cholesterol in the plasma membrane was detected indirectly by monitoring their appearance in plasma and bile. The plasma disappearance of [3H]cholesteryl linoleate was slightly faster in NP-C subjects regardless of its lipoprotein origin. Appearance of free [14C] cholesterol ill the plasma (and in bile) was essentially identical in normal and affected individuals as was the initial appearance of free [3H]cholesterol derived from HDL, observed before extensive exchange occurred of the [3H]cholesteryl linoleate among lipoproteins. In contrast, the rate of appearance of LDL-derived free [3H]cholesterol in the plasma membrane of NP-C subjects, as detected in plasma and bile, was retarded to a similar extent that LDL cholesterol metabolism was defective in cultured fibroblasts of these affected subjects. These findings show that intracellular distribution of both newly synthesized and HDL-derived cholesterol are essentially unperturbed by the NP-C mutation, and therefore occur by lysosomal-independent paths. In contrast, in NP-C there is defective trafficking of LDL-derived cholesterol to the plasma membrane in vivo as well as in vitro. The in vivo assay of intracellular cholesterol distribution developed herein should prove useful to quickly evaluate therapeutic interventions for NP-C.
尼曼-匹克C病(NP-C)是一种罕见的先天性代谢紊乱疾病,伴有肝脏受累和神经后遗症,通常在儿童期出现。尽管体外研究表明,NP-C患者培养细胞中低密度脂蛋白(LDL)衍生胆固醇的溶酶体分布存在缺陷,但血浆脂蛋白谱并无异常特征。我们着手确定在生理条件下,NP-C患者体内新合成的、高密度脂蛋白(HDL)衍生或LDL衍生胆固醇的细胞分布是否存在异常。给三名患病男性和三名正常男性受试者注射[14C]甲羟戊酸作为新合成胆固醇的示踪剂,并注射HDL或LDL中的[3H]胆固醇亚油酸酯以追踪脂蛋白衍生游离胆固醇的分布。通过监测它们在血浆和胆汁中的出现情况,间接检测质膜中游离[14C]和游离[3H]胆固醇的出现速率。无论其脂蛋白来源如何,NP-C患者中[3H]胆固醇亚油酸酯的血浆清除速度略快。正常人和患病个体中游离[14C]胆固醇在血浆(和胆汁)中的出现情况基本相同,HDL衍生的游离[3H]胆固醇在脂蛋白之间广泛交换之前的初始出现情况也是如此。相比之下,在血浆和胆汁中检测到的NP-C患者质膜中LDL衍生游离[3H]胆固醇的出现速率受到抑制,其程度与这些患病受试者培养成纤维细胞中LDL胆固醇代谢缺陷的程度相似。这些发现表明,新合成的和HDL衍生的胆固醇的细胞内分布基本上不受NP-C突变的干扰,因此是通过不依赖溶酶体的途径发生的。相比之下,在NP-C中,LDL衍生胆固醇在体内和体外向质膜的转运均存在缺陷。本文开发的细胞内胆固醇分布的体内测定方法应有助于快速评估NP-C的治疗干预措施。